九强生物(300406) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for the first quarter was ¥373,395,954.06, representing a slight increase of 0.22% compared to ¥372,581,948.21 in the same period last year[3]. - Net profit attributable to shareholders was ¥111,021,507.44, marking a 13.16% increase from ¥98,110,266.08 year-over-year[3]. - The net profit after deducting non-recurring gains and losses was ¥109,188,936.22, up 13.08% from ¥96,556,931.89 in the previous year[3]. - Basic and diluted earnings per share rose to ¥0.19, an increase of 11.76% from ¥0.17 in the previous year[3]. - The total comprehensive income for the period was approximately ¥109.70 million, compared to ¥100.16 million in the same quarter last year, representing an increase of 9.5%[30]. - The net profit for the first quarter of 2023 was approximately ¥109.94 million, an increase of 9.1% compared to ¥100.30 million in the same period last year[30]. - The net profit attributable to the parent company was approximately ¥111.02 million, up from ¥98.11 million, reflecting a growth of 13.1% year-over-year[30]. Cash Flow and Liquidity - The net cash flow from operating activities increased by 10.55% to ¥13,703,432.30, compared to ¥12,395,647.70 in the same quarter last year[3]. - The cash flow from operating activities showed significant changes, with a notable increase in cash inflows from asset disposal, which rose by 263.55% to ¥43.94 thousand compared to a loss of ¥26.87 thousand last year[38]. - Cash and cash equivalents decreased to CNY 321,963,005.37 from CNY 340,720,066.00, a decline of about 5.2%[41]. - Net cash flow from financing activities was negative at -$753,935.03, compared to -$76,282,776.55 in the previous period[53]. - The net increase in cash and cash equivalents was -$18,757,060.63, a decline from -$127,197,466.38 in the prior period[53]. Assets and Liabilities - Total assets at the end of the reporting period were ¥4,687,023,163.00, reflecting a 1.61% increase from ¥4,612,882,060.21 at the end of the previous year[3]. - Total liabilities decreased to CNY 1,309,904,781.43 from CNY 1,344,108,369.97, a decline of approximately 2.5%[42]. - Long-term borrowings increased to CNY 71,836,494.82 from CNY 49,020,823.23, reflecting a growth of about 46.5%[42]. - The total equity increased slightly to CNY 3,377,118,381.57 from CNY 3,268,773,690.24, indicating a growth of about 3.3%[42]. Expenses and Investments - The company recorded a decrease in total operating costs to ¥248,450,721.02, down from ¥259,727,100.76 in the previous year[29]. - Research and development expenses increased to ¥36,221,121.73, compared to ¥31,483,397.75 in the same period last year[29]. - Cash outflow from investment activities was CNY 34,043,057.33, down from CNY 65,777,537.94, a reduction of about 48.3%[52]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 13,231, with the largest shareholder, China Pharmaceutical Investment Co., holding 16.62%[40]. - The company completed the conversion of 848 convertible bonds into 4,798 shares of stock during the first quarter, with remaining convertible bonds totaling 11,389,152 units[23]. Future Outlook - The company plans to continue expanding its market presence and investing in new product development to drive future growth[39].